Health Information and Tools >  Eye Problems and Blood in the Eye

Main Content

Eye Problems and Blood in the Eye

Overview

Sometimes small blood vessels in the whites of the eyes break and cause a red spot or speck. This is called a subconjunctival hemorrhage. The blood vessels may break because of sneezing, coughing, vomiting, straining, or bending over, but sometimes there is no clear cause. The blood may look alarming, especially if the spot is large. It is usually not a cause for concern and will clear up in 2 to 3 weeks. Subconjunctival hemorrhage is usually not a serious problem if your vision is normal, there is no eye pain, and the bleeding does not cover a large portion of the white of the eye and does not spread into the colored part of the eye (iris).

Bleeding that occurs between the coloured part of the eye (iris) and the cornea is called a hyphema. This is more serious than bleeding that occurs in the white of the eye. You may have mild pain or no pain at all. After an eye injury, blood usually appears immediately. But if the injury is mild, blood may not appear until up to 5 days later. You may also have vision changes. A hyphema may be a more serious problem for a person who has sickle cell disease. If you have a hyphema, see an eye specialist (ophthalmologist).

Medicines that help prevent blood clots may increase the risk of bleeding in both the white or coloured part of the eye. When there is bleeding into the eye, do not take aspirin, aspirin-related products, or non-steroidal anti-inflammatory drugs (NSAIDs) for pain because they can increase bleeding. Use acetaminophen (such as Tylenol) instead.

Credits

Current as of: October 12, 2022

Author: Healthwise Staff
Medical Review:
William H. Blahd Jr. MD, FACEP - Emergency Medicine
Adam Husney MD - Family Medicine
Kathleen Romito MD - Family Medicine

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.